CeriBell, Inc.

CeriBell, Inc. (NASDAQ:CBLL) is a medical device company founded in 2014 and based in Sunnyvale, California. Originally incorporated as Brain Stethoscope, Inc., the company changed its name to CeriBell in August 2015. CeriBell has developed artificial intelligence-powered point-of-care electroencephalography (EEG) technology designed to detect and monitor neurological conditions in acute care settings. The company went public and has established itself as a leader in seizure detection technology, with its systems having been used on over 200,000 patients across more than 500 active hospital accounts.

Over the past few years, CeriBell has executed several key strategic initiatives that have significantly expanded its market opportunity and technological capabilities. The most significant recent development was the company's successful initial public offering, which raised $188 million in net proceeds and provided substantial capital for growth investments. Product Development and FDA Approvals: The company achieved a major milestone with FDA 510(k) clearance for its pediatric seizure detection algorithm in early 2025, making it the first and only FDA-cleared seizure detection algorithm for patients aged one year and above. This approval, validated with EEG data from over 700 patients, significantly expands CeriBell's addressable market into pediatric care settings. Pipeline Expansion Beyond Seizures: CeriBell has strategically diversified its technology platform to address multiple neurological conditions. The company received FDA breakthrough device designation for its delirium detection algorithm and is preparing for regulatory submission. Additionally, it has been developing stroke detection algorithms, having collected data on over 200 patients with encouraging initial results. This multi-indication approach positions CeriBell to become a comprehensive neurological monitoring platform rather than a single-purpose seizure detection device. Commercial Scale-Up: The company has been aggressively expanding its commercial organization, planning to grow from its current sales force to 55 territory managers by mid-2025. This expansion reflects confidence in market demand and the company's ability to penetrate new accounts. The company has grown from 504 active accounts to 558 accounts, adding 29 new accounts in Q1 2025 alone. Strategic Vision - EEG as a Vital Sign: Management has articulated a long-term vision of making EEG monitoring as routine as other vital signs in hospital settings. This ambitious goal involves developing algorithms for multiple neurological conditions and eventually expanding beyond acute care settings into other healthcare environments.